- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Medicenna Therapeutics Corp: Medicenna presents preclinical results in France | 1 | Stockwatch | ||
| 09.09. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 09.09. | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference | 1 | GlobeNewswire (USA) | ||
| 27.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 15.08. | Medicenna Therapeutics Corp: Medicenna Therapeutics appoints Lalji to board | 1 | Stockwatch | ||
| 15.08. | Medicenna expands board with new director | 1 | Investing.com | ||
| 15.08. | Medicenna Therapeutics Corp.: Medicenna Strengthens Board of Directors with Appointment of Karim Lalji | 1 | GlobeNewswire (USA) | ||
| 02.08. | Medicenna Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 26.07. | Medicenna Therapeutics Corp: Medicenna Therapeutics has change in transfer agent | 1 | Stockwatch | ||
| 28.06. | Medicenna Therapeutics Corp: Medicenna's March 31 cash position at $17-million | 2 | Stockwatch | ||
| 27.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights | 156 | GlobeNewswire (Europe) | Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity... ► Artikel lesen | |
| 26.06. | Medicenna Therapeutics Corp: Medicenna receives EMA approval for Ability-1 trial | 1 | Stockwatch | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe | 392 | GlobeNewswire (Europe) | - ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®... ► Artikel lesen | |
| 03.06. | RBC, Kits, Medicenna at 52-Week Highs on News | 1 | Baystreet.ca | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna presents phase 2b bizaxofusp results at ASCO | 1 | Stockwatch | ||
| 03.06. | Medicenna reveals positive results from brain cancer study | 2 | The Market Herald Canada | ||
| 03.06. | Medicenna Therapeutics Corp.: Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting | 89 | GlobeNewswire (Europe) | Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:... ► Artikel lesen | |
| 31.05. | Medicenna Therapeutics Corp.: Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation ... | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum | 1 | GlobeNewswire (USA) | ||
| 14.05. | Medicenna Therapeutics Corp. - 15-12G, Securities registration termination | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | -1,52 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,398 | +1,53 % | BioTech is back! BioNTech explodiert - was machen Bayer, Moderna, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma? | Endlich Zinssenkungen! Als hätten die BioTech-Investoren das Läuten zur Andacht bereits deutlich vernommen, bessert sich die Stimmung im bislang am meisten zurückgebliebenen Sektor in 2024. Zuletzt... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,000 | -2,37 % | Ginkgo Bioworks stock target raised, keeps buy rating on new data portfolio | ||
| RECURSION PHARMACEUTICALS | 6,810 | -1,87 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,670 | -1,42 % | Jones Trading stuft Beam Therapeutics auf "Halten" ein | ||
| ONCOLYTICS BIOTECH | 0,800 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ASSERTIO | 1,285 | -4,81 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,640 | -1,81 % | CSL And Arcturus Therapeutics Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine | CANBERA (dpa-AFX) - Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics, announced Friday that Japan's Ministry of Health, Labor and Welfare... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,435 | -1,11 % | SIGA Technologies executive takes indefinite leave | ||
| ADMA BIOLOGICS | 19,950 | +1,06 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,770 | -2,14 % | Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024.
"The positive... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,195 | -3,44 % | Jim Cramer on Verve Therapeutics Inc. (VERV): 'I Think It's A Winner' | ||
| ARS PHARMACEUTICALS | 14,790 | -0,47 % | Ars Pharmaceuticals CEO sells over $1.29 million in company stock | ||
| ARVINAS | 25,630 | +0,12 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,55 % bei einem Aktienkurs von 0,161 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.
